Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

295 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial.
Napolitano S, Ciardiello D, De Falco V, Martini G, Martinelli E, Della Corte CM, Esposito L, Famiglietti V, Di Liello A, Avallone A, Cardone C, De Stefano A, Montesarchio V, Zampino MG, Fazio N, Di Maio M, Del Tufo S, De Vita F, Altucci L, Marrone F, Ciardiello F, Troiani T. Napolitano S, et al. Among authors: de vita f. Int J Cancer. 2023 Oct 15;153(8):1520-1528. doi: 10.1002/ijc.34632. Epub 2023 Jun 30. Int J Cancer. 2023. PMID: 37391938 Clinical Trial.
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
Ciardiello F, Bianco R, Caputo R, Caputo R, Damiano V, Troiani T, Melisi D, De Vita F, De Placido S, Bianco AR, Tortora G. Ciardiello F, et al. Among authors: de placido s, de vita f. Clin Cancer Res. 2004 Jan 15;10(2):784-93. doi: 10.1158/1078-0432.ccr-1100-03. Clin Cancer Res. 2004. PMID: 14760102
The role of EGFR inhibitors in nonsmall cell lung cancer.
Ciardiello F, De Vita F, Orditura M, Tortora G. Ciardiello F, et al. Among authors: de vita f. Curr Opin Oncol. 2004 Mar;16(2):130-5. doi: 10.1097/00001622-200403000-00008. Curr Opin Oncol. 2004. PMID: 15075904 Review.
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.
Tuccillo C, Romano M, Troiani T, Martinelli E, Morgillo F, De Vita F, Bianco R, Fontanini G, Bianco RA, Tortora G, Ciardiello F. Tuccillo C, et al. Among authors: de vita f. Clin Cancer Res. 2005 Feb 1;11(3):1268-76. Clin Cancer Res. 2005. PMID: 15709198
Capecitabine plus weekly oxaliplatin in gastrointestinal tumors: a phase I study.
Carlomagno C, Orditura M, Pepe S, De Vita F, Romano C, Ciardiello F, Ferrara C, Martinelli E, Bianco R, Aurilio G, D'Agostino D, Tortora G, Catalano G, De Placido S. Carlomagno C, et al. Among authors: de placido s, de vita f. Am J Clin Oncol. 2006 Feb;29(1):85-9. doi: 10.1097/01.coc.0000195087.24930.e7. Am J Clin Oncol. 2006. PMID: 16462509 Clinical Trial.
Cetuximab in the treatment of colorectal cancer.
Ciardiello F, De Vita F, Orditura M, Comunale D, Galizia G. Ciardiello F, et al. Among authors: de vita f. Future Oncol. 2005 Apr;1(2):173-81. doi: 10.1517/14796694.1.2.173. Future Oncol. 2005. PMID: 16555987 Review.
295 results